These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38977151)

  • 21. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
    Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
    JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
    Trojaniello C; Vitale MG; Ascierto PA
    Curr Opin Oncol; 2021 Mar; 33(2):133-138. PubMed ID: 33399314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis.
    Mincu RI; Mahabadi AA; Michel L; Mrotzek SM; Schadendorf D; Rassaf T; Totzeck M
    JAMA Netw Open; 2019 Aug; 2(8):e198890. PubMed ID: 31397860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incident Noninfectious Uveitis Risk after Immune Checkpoint Inhibitor Treatment.
    Chang MS; Lee SW; Kim S; Lee CS; Byeon SH; Kim SS; Kim YJ
    Ophthalmology; 2024 Jul; 131(7):867-869. PubMed ID: 38522600
    [No Abstract]   [Full Text] [Related]  

  • 26. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
    Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
    Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
    Kim HW; Kim JS; Lee SH
    Lung Cancer; 2021 Aug; 158():107-114. PubMed ID: 34146757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.
    Qin H; Yan H; Chen Y; Xu Q; Huang Z; Jiang W; Wang Z; Deng L; Zhang X; Zhang L; Yang N; Zeng L; Zhang Y
    BMC Cancer; 2024 Aug; 24(1):952. PubMed ID: 39097705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line immunotherapy versus targeted therapy in patients with
    Pavlick AC; Zhao R; Lee CH; Ritchings C; Rao S
    Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
    Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors.
    Lai-Kwon J; Khoo C; Lo S; Milne D; Mohamed M; Raleigh J; Smith K; Lisy K; Sandhu S; Jefford M
    J Cancer Surviv; 2019 Aug; 13(4):503-511. PubMed ID: 31165342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.
    Yamaguchi T; Shimizu J; Matsuzawa R; Watanabe N; Horio Y; Fujiwara Y
    BMC Cancer; 2024 Jul; 24(1):842. PubMed ID: 39009968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
    Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
    JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
    Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
    ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.
    Berger M; Amini-Adlé M; Maucort-Boulch D; Robinson P; Thomas L; Dalle S; Courand PY
    Cancer Med; 2020 Apr; 9(8):2611-2620. PubMed ID: 32056395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.